MedlinevsMerck & Company

MDLN and MRK stock compared: price, dividend, valuation and results, from SEC filings.

MDLN

Medline Inc.

$38.49

Value $31.2B

-1.81%
MDLN's page

MRK

Merck & Company, Inc.

$142.88

Value $353B

-0.69%
MRK's page

Medline (MDLN) has a market value of $31.2B and Merck & Company (MRK) $353B. The P/E is 53.6 for MDLN and 144.0 for MRK. Dividend yield: MDLN none, MRK 2.38%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MDLN$31.2B

    MRK$353B

    MRK is 11 times MDLN

  • Revenue, 12 months

    MDLN$30.7B

    MRK$67.4B

    MRK is 2.2 times MDLN

  • Net income, 12 months

    MDLN$582M

    MRK$2.5B

    MRK is 4.2 times MDLN

  • Operating margin

    MDLN5.7%

    MRK–

  • ROIC

    MDLN5.7%

    MRK3.9%

    1.8 points apart

  • P/E

    MDLN53.6

    MRK144.0

    MRK is 2.7 times MDLN

  • Dividend yield

    MDLN0.0%

    MRK2.4%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MDLN-6.2%

MRK+47.1%

751001251502026

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MDLNMedlineMRKMerck & Company

Valuation

MDLNMRK
Valuation
Price$38.49$142.88
Market value$31.2B$353B
Enterprise value (EV)$40.1B$397B
P/E53.6144.0
P/E, 5-year median–14.8
P/B2.67.9
EV/EBIT23.183.5
Free cash flow yield6.1%4.2%

Results and growth

MDLNMRK
Results and growth
Revenue, 12 months$30.7B$67.4B
Net income, 12 months$582M$2.5B
Free cash flow, 12 months$1.9B$14.7B
Earnings per share, 12 months$0.72$0.98
Revenue growth, year on year11.5%1.3%
Revenue growth a year, past+10.6%over 2 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

MDLNMRK
Margins and returns on capital
Gross margin25.7%71.8%
Operating margin5.7%–
Net margin1.9%3.6%
ROIC5.7%3.9%
ROE5.4%5.2%

Balance sheet

MDLNMRK
Balance sheet
Cash$3.6B$9.7B
Total debt$12.6B$53.8B
Net debt / EBITDA3.35.7
Interest cover2.5×2.4×

Dividends and buybacks

MDLNMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield0.1%1.4%
Shareholder yield0.1%3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MDLN or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Medline or Merck & Company?

By market value, Merck & Company ($353B) is about 11.3 times Medline ($31.2B), at today's prices.

Which pays the higher dividend, MDLN or MRK?

The dividend yield at today's price is none for Medline and 2.38% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of MDLN and MRK?

At today's price, the P/E is 53.6 for MDLN and 144.0 for MRK. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Medline or Merck & Company?

Over the last twelve months, the net margin was 1.9% for Medline and 3.6% for Merck & Company, and the operating margin 5.7% and –. Revenue was $30.7B and $67.4B.

Which is the better investment, Medline or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.